John Fontenault Joins as Vice President of Operations
Michelle King Added as Director, Early Phase Consulting
FORT LAUDERDALE, Fla., Nov. 11, 2013 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTC:OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced the addition of two industry experts to their organization.
Mr. John Fontenault has joined OmniComm as Vice President of Operations. A clinical data operations and data systems executive and 24 year veteran of the pharmaceutical industry, he brings a depth of practical expertise to OmniComm. Most recently as Vice President, Operations at ER Squared, Mr. Fontenault provided strategic eclinical business process and technology change management and adoption services to large and small sized sponsors and CROs. Prior to ER Squared, Mr. Fontenault was Executive Director and Global Head of Clinical Data Management and Technology at Kendle International (INC Research) where he was responsible for a staff of 500 in 13 locations worldwide. Prior to Kendle, Mr. Fontenault was Associate Director at Bayer where he led pioneering efforts in electronic data capture design and implementation. Mr. Fontenault will be responsible for all aspects of the Software-as-a-Service Operational delivery team including study builds, clinical analysis, project management, deployment, and customer care.
"My career has offered me the opportunity to not only provide eclinical services but also receive these services as a customer. During my recent position at Kendle, I developed a relationship with OmniComm and was quite impressed the people, the leadership, and of course the technology. I am very happy to be part of this organization and to lead this team of talented individuals. I am dedicated to operational excellence and look forward to sharing insights from years in the field with OmniComm's clients and colleagues."
Ms. Michelle King has joined OmniComm as Director, Early Phase Consulting. Ms. King comes to OmniComm from Instem (formerly Logos Technologies) and brings over a decade of hands-on research experience. She has specific expertise in implementation of real time data capture systems, training and management of phase I clinical sites globally. Prior to Logos, Ms. King was a Clinic Manager responsible for multiple Phase I, Phase IIa, and BA/BE projects in several therapeutic areas.
"Having managed early phase research studies, I am keenly aware of the challenges clinics face and the tools that are needed to be successful," states Ms. King. "I am excited to offer innovative solutions to and build strong relationships with OmniComm's current and future early phase clients."
"It is a testament to OmniComm that we continue to attract high caliber talent to our team," said Stephen Johnson, President and COO of OmniComm. "As hands-on users of EDC systems in their prior positions at sponsors and clinic sites, John and Michelle have a tremendous understanding of the needs of our customers. They are exceptionally well suited to enhance OmniComm's commitment to delivering high quality, innovative technologies and exceptional service. I'm thrilled to welcome them both to OmniComm."
About OmniComm Systems
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.